Cibus, Inc. Announces Proposed Public Offering of Class A Common Stock and Pre-Funded Warrants
Rhea-AI Summary
Cibus (Nasdaq: CBUS) announced a proposed underwritten public offering of Class A common stock and pre-funded warrants on March 25, 2026. The company expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares offered. Net proceeds are intended for working capital and to fund development of weed management traits in rice. The securities will be offered from an effective Form S-3 shelf registration (File No. 333-273062) and a prospectus supplement will be filed with the SEC. The Offering is subject to market and other conditions and may not be completed.
Positive
- Access to capital for working capital and development
- Proceeds targeted to fund weed management traits in rice
- Offering covered by effective Form S-3 registration
Negative
- Potential shareholder dilution from the offering and pre-funded warrants
- Underwriter option could increase issuance by up to 15%
- Offering completion is uncertain and subject to market conditions
News Market Reaction – CBUS
In the Mar 26 session, CBUS declined 25.78%, reflecting a significant negative market reaction. Argus tracked a trough of -19.0% from its starting point during tracking. Our momentum scanner triggered 34 alerts that day, indicating elevated trading interest and price volatility. Trading volume was above average at 1.7x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 29 | Offering pricing | Negative | +9.1% | Priced $20M stock offering at $1.50 with board participation. |
| Jan 28 | Offering proposed | Negative | +9.1% | Announced proposed underwritten equity offering under existing shelf. |
| Jun 09 | Offering closing | Negative | -0.6% | Closed $27.5M equity raise at $1.75 per share. |
| Jun 05 | Offering pricing | Negative | -34.3% | Priced $27.5M stock offering; chairman participated heavily. |
| Jun 04 | Offering proposed | Negative | -34.3% | Proposed equity raise to fund Rice traits and working capital. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Equity offerings have often pressured the stock (average move -10.21%), though the January 2026 raise produced a positive reaction, showing mixed responses to financing events.
Over the past year, Cibus has repeatedly tapped equity markets to fund development of weed management traits in Rice and working capital. Prior offering announcements and pricings in June 2025 led to sharp declines of up to -34.32%, while the January 2026 proposed and priced offerings each saw +9.09% moves. All these financings shared similar use-of-proceeds language, linking capital raises directly to its Rice trait pipeline and general corporate needs.
Key Terms
pre-funded warrants financial
underwritten public offering financial
prospectus supplement regulatory
base prospectus regulatory
preliminary prospectus supplement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, March 25, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced that it intends to offer shares of its Class A common stock, par value
BTIG, LLC is acting as the sole underwriter for the Offering.
Cibus currently intends to use the net proceeds from the Offering for working capital and general corporate purposes, including to fund further development of its weed management traits in Rice.
The securities will be offered pursuant to an effective shelf registration statement on Form S-3 (File No. 333-273062), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on June 30, 2023, as amended on October 25, 2023, and declared effective by the SEC on October 27, 2023. A prospectus supplement describing the terms of the Offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Copies of the prospectus supplement and the accompanying base prospectus, when available, may be obtained from BTIG, LLC, at 65 East 55th Street, New York, New York 10022 or by telephone at (212) 593-7555, or by email at ProspectusDelivery@btig.com. Before investing in this Offering, interested parties should read in their entirety the preliminary prospectus supplement and the accompanying prospectus and the other documents that Cibus has filed with the SEC that are incorporated by reference in such preliminary prospectus supplement and the accompanying prospectus, which provide more information about Cibus and such Offering.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Cibus
Cibus is a leader in developing traits (characteristics) that address critical productivity, yield and sustainability challenges. Cibus’ proprietary high-throughput gene editing technologies drive its long-term focus on productivity traits for farmers for the major global row crops. Cibus is not a seed company. It is a technology company that uses its gene editing technologies to develop plant traits at a fraction of the time and cost of conventional breeding and to license them to customers in exchange for royalties.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “anticipates,” “believes,” “continue,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “predicts,” “projects,” “should,” “targets,” “will,” or the negative of these terms and other similar terminology. Forward-looking statements in this press release include, but are not limited to, statements regarding the anticipated Offering and the expected use of the proceeds therefrom. Completion of the Offering is subject to numerous factors, many of which are beyond Cibus’ control, including, without limitation, market conditions, failure to satisfy customary closing conditions and the risk factors and other matters set forth in the prospectus supplement and accompanying prospectus included in the registration statement and the documents incorporated by reference therein. You are cautioned not to place undue reliance on any forward-looking statements, which are based only on information currently available to it when, and speak only as of the date, such statement is made. Cibus does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law.
CIBUS CONTACTS:
INVESTOR RELATIONS
Jeff Sonnek – ICR
jeff.sonnek@icrinc.com
MEDIA RELATIONS
media@cibus.com
Colin Sanford
colin@bioscribe.com
203-918-4347
